Interesting.
It just so happens that an Australian company with a very similar name and profile is preparing for an IPO. The Australian version runs clinical trials for biotech companies.
Australian Financial Review article here.
dest's overwrite journal
- Thread starter destriero
- Start date
- Status
It just so happens that an Australian company with a very similar name and profile is preparing for an IPO. The Australian version runs clinical trials for biotech companies.
Australian Financial Review article here.
Same Tickler Symbol? That not related to- the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, managing Novo Nordisk Foundation's assets?
Heck, you may be right, what's your verdict?
NVO has about 20 drugs in various stages of phase 3 trials.
You guys are trying to figure out what's up by posting/interpreting charts on a giant multi-nat....
Hmmmmm, I wonder if the FDA or EMA bases their decisions on stock charts?
Hmmmm?
"But that's always worked before when predicting large moves in biotechs".
Yeah right....
Like absolutely NEVER.
EDIT:
Duck VZ...Here it comes....
Last edited:
So, EVERY biotech has about 20 drugs in various stages of phase-3 trials. And their chart patterns prolly look similar.
What does NVO have that the others do not have, for Dest to make the call? He's got an angle on something.
Hehe, dare I say, he's got a little WSB in him? (Well, not really, that would be insulting.)
No idea.... but I'll listen to him before I try to figure it using a chart.
And NO.... every biotech DOES NOT have 20+ drugs in phase 3 trials.
How do you know that?
Completely understand where you're coming from there, what I'm talking about though are biotech's in particular.
The giant moves are always gaps. There's no warning, at least there shouldn't be if there's no insider type leaks. There might be some tells in advance, a big option purchase or some unusual volume in the days/weeks leading up to an FDA approval, but with a company as big as NVO I doubt a solid chart is a harbinger of anything more than a solid company.
Now with that said, imagine they break news that that FDA has approved some revolutionary obesity pill that will make fatties forever obsolete. There's gonna be a decent gap, morso for a smaller clinical stage player than NVO, but even NVO will gap some. So yeah there'll be plenty of action after the fact, but D's post hints of a gap based on an approval of something big.
Because lol, Stoney and I look at different ones all week long. For one thing phase 3 is a big deal, aside from the big players like PFE, JNJ, MRK, NVo, etc... most of these clinical stage operations working on a cutting edge drug have only a handful of candidates, with perhaps one, maybe two, in phase 3. The whole approval process gets pretty complicated when you dig into it. Even the various stages within the various phases.
- Status